Literature DB >> 6354778

Glycosylated insulin complexed to Concanavalin A. Biochemical basis for a closed-loop insulin delivery system.

M Brownlee, A Cerami.   

Abstract

The oligosaccharides maltose, maltotriose, mannotriose, and mannotetrose have been chemically attached to insulin molecules. Incubation of oligosaccharide and insulin at different molar ratios, with or without addition of cyanoborohydride, showed a nearly linear increase in carbohydrate attachment over time. The intravenous t1/2 of 125I-labeled sugar-insulin derivatives was identical to that of unmodified insulin (3.0 min). Biologic activity of these derivatives, assessed in rats by use of a blood glucose depression assay, did not differ significantly from control. These glycosylated insulin molecules are reversibly bound to the glucose-binding lectin Concanavalin A (Con A). Such sugar-insulin/lectin complexes serve as an insulin reservoir from which sugar-insulin molecules are displaced by glucose. Release of sugar-insulin molecules is a function of the particular sugar-insulin and of the ambient glucose concentration. Glucose displacement of glycosylated insulin complexed to Con A is in direct proportion to the amount of glucose present in the surrounding fluid. At each glucose concentration, the relative binding affinity of the maltotriose derivative is less than that of the mannotriose derivative, while the relative binding affinity of both maltotriose and mannotriose are less than that of the mannotetrose derivative. Prolonged incubation at 37 degrees C causes sugar-insulin, like unmodified insulin, to spontaneously aggregate into high-mol-wt, nondiffusable complexes. This aggregation phenomenon was found to be markedly inhibited when glycosylated insulins were synthesized utilizing partially sulfated insulin. Results from the studies described in this report provide the biochemical basis for a closed-loop, glucose-controlled insulin delivery system, utilizing glycosylated insulin complexed to Con A.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6354778     DOI: 10.2337/diab.32.6.499

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  16 in total

Review 1.  Optimisation of treatment by applying programmable rate-controlled drug delivery technology.

Authors:  Yie W Chien; Senshang Lin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering.

Authors:  Daniel F Berenson; Allison R Weiss; Zhu-Li Wan; Michael A Weiss
Journal:  Ann N Y Acad Sci       Date:  2012-03-13       Impact factor: 5.691

Review 3.  Recent developments in insulin delivery techniques. Current status and future potential.

Authors:  F P Kennedy
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

Review 4.  Glucose-Responsive Insulin and Delivery Systems: Innovation and Translation.

Authors:  Jinqiang Wang; Zejun Wang; Jicheng Yu; Anna R Kahkoska; John B Buse; Zhen Gu
Journal:  Adv Mater       Date:  2019-08-18       Impact factor: 30.849

Review 5.  Development of glucose-responsive 'smart' insulin systems.

Authors:  Nischay K Rege; Nelson F B Phillips; Michael A Weiss
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-08       Impact factor: 3.243

Review 6.  The pursuit of perfect control in diabetes.

Authors:  J Pickup
Journal:  BMJ       Date:  1988-10-15

7.  Lifetime-based sensing of glucose using energy transfer with a long lifetime donor.

Authors:  L Tolosa; H Szmacinski; G Rao; J R Lakowicz
Journal:  Anal Biochem       Date:  1997-07-15       Impact factor: 3.365

8.  A glucose-responsive insulin therapy protects animals against hypoglycemia.

Authors:  Ruojing Yang; Margaret Wu; Songnian Lin; Ravi P Nargund; Xinghai Li; Theresa Kelly; Lin Yan; Ge Dai; Ying Qian; Qing Dallas-Yang; Paul A Fischer; Yan Cui; Xiaolan Shen; Pei Huo; Danqing Dennis Feng; Mark D Erion; David E Kelley; James Mu
Journal:  JCI Insight       Date:  2018-01-11

9.  Determination of peritoneal glucose kinetics in rats: implications for the peritoneal implantation of closed-loop insulin delivery systems.

Authors:  G Velho; P Froguel; G Reach
Journal:  Diabetologia       Date:  1989-06       Impact factor: 10.122

10.  Bioresponsive Microneedles with a Sheath Structure for H2 O2 and pH Cascade-Triggered Insulin Delivery.

Authors:  Yuqi Zhang; Jinqiang Wang; Jicheng Yu; Di Wen; Anna R Kahkoska; Yue Lu; Xudong Zhang; John B Buse; Zhen Gu
Journal:  Small       Date:  2018-02-26       Impact factor: 13.281

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.